Heron Therapeutics Reveals APONVIE® (aprepitant) Injectable Emulsion Added to Updated Fifth Consensus Guidelines for Postoperative Nausea and Vomiting (PONV) Management
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 04 2025
0mins
Should l Buy HRTX?
Source: Yahoo Finance
APONVIE Overview: APONVIE is the only FDA-approved IV formulation of the NK-1 antagonist aprepitant, indicated for preventing postoperative nausea and vomiting (PONV) in adults, with a rapid onset and long half-life compared to oral alternatives.
Efficacy in PONV Prevention: Aprepitant, whether used alone or in combination with other therapies, significantly reduces the risk of PONV and is more effective than 5-HT3 receptor antagonists, making it a preferred choice for postoperative care.
Guidelines for Postoperative Care: The newly released PONV Guidelines emphasize the importance of long-acting antiemetics like APONVIE to mitigate post-discharge nausea and vomiting (PDNV), which affects a significant number of patients after surgery.
Clinical Implications: The guidelines advocate for a multimodal approach to PONV prevention, particularly for high-risk patients, highlighting the need for clinicians to be aware of and adhere to these recommendations to enhance patient recovery experiences.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HRTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HRTX
Wall Street analysts forecast HRTX stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.988
Low
3.00
Averages
4.50
High
6.00
Current: 0.988
Low
3.00
Averages
4.50
High
6.00
About HRTX
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. It creates and commercializes a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. Its acute care product portfolio includes ZYNRELEF and APONVIE. Its oncology care product portfolio includes CINVANTI and SUSTOL. ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is an intravenous formulation of a substance P/neurokinin-1 (NK1) receptor antagonist indicated for postoperative nausea and vomiting (PONV). CINVANTI is an IV formulation of aprepitant, a substance NK1 receptor antagonist. SUSTOL is an extended-release 5-HT3 receptor antagonist for the prevention of acute and delayed nausea and vomiting.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Heron (HRTX) Q4 2025 Earnings Call Transcript
See More
Heron Therapeutics Q4 2025 Earnings Highlights
- Successful Financing Completion: CEO Craig Collard emphasized the successful completion of financing, describing it as a 'meaningful derisking event' that allows the company to focus on commercial execution and product expansion, thereby driving sustained growth.
- Strong Financial Performance: Full-year net revenues for 2025 reached approximately $155 million, with adjusted EBITDA of $14.7 million, exceeding prior guidance of $9 million to $13 million, showcasing the company's financial robustness and growth potential.
- Acute Care Product Line Growth: ZYNRELEF achieved a 48% net revenue growth in Q4, while APONVIE grew by 97%, leading to an overall year-over-year increase of over 57% in the Acute Care franchise, indicating the company's strengthening competitive position in the market.
- Optimistic 2026 Outlook: Management raised the 2026 net product sales guidance to $173 million to $183 million, with expectations of EBITDA positivity, reflecting confidence in commercial expansion and the strategic necessity of targeted investments.
See More
Heron Therapeutics Q4 Earnings Report Analysis
- Earnings Performance: Heron Therapeutics reported a Q4 GAAP EPS of -$0.02, missing estimates by $0.01, although revenue reached $40.59 million, a slight 0.5% year-over-year decline, yet exceeding market expectations by $1.06 million, indicating some effectiveness in revenue management.
- Acute Care Growth: The Acute Care franchise achieved a remarkable 57.3% year-over-year revenue growth in Q4 2025 and 65.1% for the full year compared to 2024, suggesting strong market demand in this segment, potentially laying the groundwork for sustained future growth.
- Cash Position: As of December 31, 2025, Heron reported cash, cash equivalents, and short-term investments totaling $46.6 million, reflecting robust liquidity management that supports future operations and investments.
- 2026 Financial Guidance: Heron provided a 2026 net revenue guidance of $173 to $183 million and an adjusted EBITDA forecast of $10 to $20 million, both exceeding the consensus estimate of $171.73 million, demonstrating the company's confidence in its future performance.
See More
Heron Therapeutics to Announce Q4 Earnings on February 26
- Earnings Announcement Date: Heron Therapeutics (HRTX) is set to announce its Q4 2023 earnings on February 26 before the market opens, drawing significant attention from investors regarding its performance.
- Earnings Expectations: The consensus EPS estimate stands at -$0.03, indicating potential profitability challenges that could affect investor confidence in the company's financial health.
- Revenue Projections: The revenue estimate is $39.53 million, reflecting a 3.1% year-over-year decline, which suggests that the company is facing challenges in a competitive market environment that may impact future growth prospects.
- Historical Performance Review: Over the past year, HRTX has beaten EPS estimates 50% of the time and revenue estimates 75% of the time, indicating that the company has a track record of exceeding expectations to some extent.
See More
Heron Therapeutics Reports Q4 2025 Net Revenue of $40.5M Driven by ZYNRELEF and APONVIE
- Revenue Growth: Heron Therapeutics reported approximately $40.5 million in net revenue for Q4 2025, reflecting significant growth compared to the previous year, driven particularly by strong momentum in its Acute Care franchise, especially ZYNRELEF and APONVIE.
- Product Performance: ZYNRELEF generated approximately $12.5 million in net revenue in Q4, marking the largest quarter-over-quarter revenue increase within the portfolio, indicating successful market acceptance and sales strategies.
- Diversified Revenue Streams: CINVANTI and APONVIE contributed approximately $22.9 million and $3.8 million in net revenue for Q4, respectively, enhancing the diversity of the company's revenue sources and reducing reliance on any single product.
- Annual Performance: Total net revenue for FY25 was approximately $154.9 million, reflecting ongoing progress and growth potential across all business areas, suggesting a positive outlook for future developments.
See More
Heron Therapeutics Reports $154.9M Net Revenue for 2025
- Revenue Growth: Heron Therapeutics reported approximately $40.5 million in net revenue for Q4 2025, reflecting strong momentum in its Acute Care franchise, particularly driven by ZYNRELEF® and APONVIE®.
- Product Performance: ZYNRELEF® generated about $12.5 million in net revenue in Q4, marking a ~35% increase from Q3, indicating sustained demand in the postoperative pain management market and enhancing the company's competitive edge.
- Diversified Revenue Streams: CINVANTI® and SUSTOL® achieved net revenues of approximately $22.9 million and $1.3 million in Q4, respectively, further solidifying Heron's market position in the prevention of chemotherapy-induced nausea and vomiting.
- Strategic Outlook: With total net revenue of approximately $154.9 million for 2025, Heron demonstrates ongoing innovation and market expansion capabilities in the biotechnology sector, laying a solid foundation for future growth.
See More
Heron (HRTX) Q4 2025 Earnings Call Transcript
See More
Heron Therapeutics Q4 2025 Earnings Highlights
- Successful Financing Completion: CEO Craig Collard emphasized the successful completion of financing, describing it as a 'meaningful derisking event' that allows the company to focus on commercial execution and product expansion, thereby driving sustained growth.
- Strong Financial Performance: Full-year net revenues for 2025 reached approximately $155 million, with adjusted EBITDA of $14.7 million, exceeding prior guidance of $9 million to $13 million, showcasing the company's financial robustness and growth potential.
- Acute Care Product Line Growth: ZYNRELEF achieved a 48% net revenue growth in Q4, while APONVIE grew by 97%, leading to an overall year-over-year increase of over 57% in the Acute Care franchise, indicating the company's strengthening competitive position in the market.
- Optimistic 2026 Outlook: Management raised the 2026 net product sales guidance to $173 million to $183 million, with expectations of EBITDA positivity, reflecting confidence in commercial expansion and the strategic necessity of targeted investments.
See More
Heron Therapeutics Q4 Earnings Report Analysis
- Earnings Performance: Heron Therapeutics reported a Q4 GAAP EPS of -$0.02, missing estimates by $0.01, although revenue reached $40.59 million, a slight 0.5% year-over-year decline, yet exceeding market expectations by $1.06 million, indicating some effectiveness in revenue management.
- Acute Care Growth: The Acute Care franchise achieved a remarkable 57.3% year-over-year revenue growth in Q4 2025 and 65.1% for the full year compared to 2024, suggesting strong market demand in this segment, potentially laying the groundwork for sustained future growth.
- Cash Position: As of December 31, 2025, Heron reported cash, cash equivalents, and short-term investments totaling $46.6 million, reflecting robust liquidity management that supports future operations and investments.
- 2026 Financial Guidance: Heron provided a 2026 net revenue guidance of $173 to $183 million and an adjusted EBITDA forecast of $10 to $20 million, both exceeding the consensus estimate of $171.73 million, demonstrating the company's confidence in its future performance.
See More
Heron Therapeutics to Announce Q4 Earnings on February 26
- Earnings Announcement Date: Heron Therapeutics (HRTX) is set to announce its Q4 2023 earnings on February 26 before the market opens, drawing significant attention from investors regarding its performance.
- Earnings Expectations: The consensus EPS estimate stands at -$0.03, indicating potential profitability challenges that could affect investor confidence in the company's financial health.
- Revenue Projections: The revenue estimate is $39.53 million, reflecting a 3.1% year-over-year decline, which suggests that the company is facing challenges in a competitive market environment that may impact future growth prospects.
- Historical Performance Review: Over the past year, HRTX has beaten EPS estimates 50% of the time and revenue estimates 75% of the time, indicating that the company has a track record of exceeding expectations to some extent.
See More
Heron Therapeutics Reports Q4 2025 Net Revenue of $40.5M Driven by ZYNRELEF and APONVIE
- Revenue Growth: Heron Therapeutics reported approximately $40.5 million in net revenue for Q4 2025, reflecting significant growth compared to the previous year, driven particularly by strong momentum in its Acute Care franchise, especially ZYNRELEF and APONVIE.
- Product Performance: ZYNRELEF generated approximately $12.5 million in net revenue in Q4, marking the largest quarter-over-quarter revenue increase within the portfolio, indicating successful market acceptance and sales strategies.
- Diversified Revenue Streams: CINVANTI and APONVIE contributed approximately $22.9 million and $3.8 million in net revenue for Q4, respectively, enhancing the diversity of the company's revenue sources and reducing reliance on any single product.
- Annual Performance: Total net revenue for FY25 was approximately $154.9 million, reflecting ongoing progress and growth potential across all business areas, suggesting a positive outlook for future developments.
See More
Heron Therapeutics Reports $154.9M Net Revenue for 2025
- Revenue Growth: Heron Therapeutics reported approximately $40.5 million in net revenue for Q4 2025, reflecting strong momentum in its Acute Care franchise, particularly driven by ZYNRELEF® and APONVIE®.
- Product Performance: ZYNRELEF® generated about $12.5 million in net revenue in Q4, marking a ~35% increase from Q3, indicating sustained demand in the postoperative pain management market and enhancing the company's competitive edge.
- Diversified Revenue Streams: CINVANTI® and SUSTOL® achieved net revenues of approximately $22.9 million and $1.3 million in Q4, respectively, further solidifying Heron's market position in the prevention of chemotherapy-induced nausea and vomiting.
- Strategic Outlook: With total net revenue of approximately $154.9 million for 2025, Heron demonstrates ongoing innovation and market expansion capabilities in the biotechnology sector, laying a solid foundation for future growth.
See More
